Immix Biopharma, Inc. - Common Stock, par value $0.0001 per share (IMMX)

CUSIP: 45258H106

Q2 2023 13F Holders as of 30 Jun 2023

Type / Class
Equity / Common Stock, par value $0.0001 per share
Shares outstanding
53,060,943
Total 13F shares
633,819
Share change
+233,023
Total reported value
$1,705,059
Price per share
$2.69
Number of holders
17
Value change
+$653,633
Number of buys
9
Number of sells
7

Quarterly Holders Quick Answers

What is CUSIP 45258H106?
CUSIP 45258H106 identifies IMMX - Immix Biopharma, Inc. - Common Stock, par value $0.0001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Top shareholders of IMMX - Immix Biopharma, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Holder Source Role / Reporting Ownership % Shares Holdings Value 12M Net Δ As of Details
Vladimir P. Torchilin
3/4/5
Scientific Co-Founder
class O/S missing
905,200
$4,230,905 20 Dec 2021
Sean Senn
3/4/5
Under 10% owner
class O/S missing
899,800
$4,205,665 14 Jul 2022
VANGUARD GROUP INC
13F
Company
0.2%
105,357
$191,750 31 Mar 2023
13F
UMB Bank, n.a.
13F
Company
0.19%
99,300
$180,726 31 Mar 2023
13F
GEODE CAPITAL MANAGEMENT, LLC
13F
Company
0.15%
79,722
$145,094 31 Mar 2023
13F
STATE STREET CORP
13F
Company
0.08%
42,960
$78,187 31 Mar 2023
13F
Moss Adams Wealth Advisors LLC
13F
Company
0.04%
20,078
$36,542 31 Mar 2023
13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP
13F
Company
0.03%
17,723
$32,256 31 Mar 2023
13F
InterOcean Capital Group, LLC
13F
Company
0.03%
15,900
$28,938 31 Mar 2023
13F
Ground Swell Capital, LLC
13F
Company
0.02%
10,692
$19,459 31 Mar 2023
13F
Tower Research Capital LLC (TRC)
13F
Company
0.01%
6,375
$12,000 31 Mar 2023
13F
UBS Group AG
13F
Company
0%
2,301
$4,188 31 Mar 2023
13F
OSAIC HOLDINGS, INC.
13F
Company
0%
350
$637 31 Mar 2023
13F
WELLS FARGO & COMPANY/MN
13F
Company
0%
38
$69 31 Mar 2023
13F

Institutional Holders of Immix Biopharma, Inc. - Common Stock, par value $0.0001 per share (IMMX) as of Q2 2023

As of 30 Jun 2023, Immix Biopharma, Inc. - Common Stock, par value $0.0001 per share (IMMX) was held by 17 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 633,819 shares. The largest 10 holders included Lynwood Capital Management Inc., VANGUARD GROUP INC, UMB Bank, n.a., GEODE CAPITAL MANAGEMENT, LLC, Koshinski Asset Management, Inc., STATE STREET CORP, COMMONWEALTH EQUITY SERVICES, LLC, Moss Adams Wealth Advisors LLC, InterOcean Capital Group, LLC, and BlackRock Inc.. This page lists 17 institutional shareholders reporting positions in this security for the Q2 2023 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period

Compare Q2 2023 vs Q1 2023 Across Filers

Q1 2023 holders
12
Q2 2023 holders
17
Holder diff
5
Investor Q1 2023 Shares Q2 2023 Shares Share Diff Share Chg % Q1 2023 Value $ Q2 2023 Value $ Value Diff $ Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .